All Posts
Review | Management of heart failure with reduced ejection fraction.
8 Nov, 2022 | 12:17h | UTCManagement of heart failure with reduced ejection fraction – Heart
Review | Intravenous fluid therapy in patients with severe acute pancreatitis admitted to the intensive care unit.
8 Nov, 2022 | 12:15h | UTCRelated:
Aggressive or Moderate Fluid Resuscitation in Acute Pancreatitis – New England Journal of Medicine (link to abstract – $ for full-text)
Acute Pancreatitis: Diagnosis and Treatment – Drugs
Evidence-Based Disposition of Acute Pancreatitis – emDocs
Pancreatitis – National Institute for Health and Care Excellence
RCT | After an out-of-hospital cardiac arrest, fever prevention for 36 vs. 72 hours resulted in similar outcomes.
8 Nov, 2022 | 12:23h | UTCDuration of Device-Based Fever Prevention after Cardiac Arrest – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this trial involving patients after out-of-hospital cardiac arrest, fever prevention for 36 or 72 hours did not result in different percentages of patients dying or having severe disability or coma. #AHA22 https://t.co/Cx6x4RfqCE pic.twitter.com/vGSb0iVISN
— NEJM (@NEJM) November 6, 2022
RCT | Efficacy of a targeted-release formulation of budesonide for treating primary immunoglobulin A nephropathy.
8 Nov, 2022 | 12:14h | UTCCommentary: Oral Steroid Safely Treats IgA Nephropathy: Trial Published – Medscape (free registration required)
Commentary on Twitter (thread – click for more)
https://twitter.com/hswapnil/status/1582685958881021952
RCT | Precuneus magnetic stimulation for Alzheimer’s disease.
8 Nov, 2022 | 12:12h | UTCPrecuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial – Brain
Commentary: Novel Approach to TMS May Slow Cognitive Decline in Alzheimer’s – Medscape (free registration required)
Commentary on Twitter
In a randomized, double-blind, phase II trial, Koch et al. find that 24 weeks of repetitive transcranial magnetic stimulation of the precuneus slows down cognitive and functional decline in patients with Alzheimer’s disease. https://t.co/jODfVG3GAJ pic.twitter.com/p9ncGTfS7J
— Brain (@Brain1878) October 27, 2022
Single-arm P2 study | Neoadjuvant relatlimab and nivolumab in resectable melanoma.
8 Nov, 2022 | 12:11h | UTCNeoadjuvant relatlimab and nivolumab in resectable melanoma – Nature
News Release: Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma – MD Anderson News Release
Commentary on Twitter
In a phase II trial of neoadjuvant & adjuvant nivolumab+relatlimab in 30 pts with stage III or oligometastatic stage IV melanoma, the pCR rate was 57%, with a 70% pRR; 1- & 2-yr RFS was 100% & 92% vs 88% & 55% for pts with vs without any path. response: https://t.co/2ypNeUTpwb
— NatureRevClinOncol (@NatRevClinOncol) November 1, 2022
Review | Targeted temperature management in postresuscitation care after incorporating results of the TTM2 Trial.
8 Nov, 2022 | 12:09h | UTCRelated:
Temperature Control After In-Hospital Cardiac Arrest: A Randomized Clinical Trial – Circulation
Hypothermic versus Normothermic Temperature Control after Cardiac Arrest – NEJM Evidence
ERC-ESICM guidelines on temperature control after cardiac arrest in adults – Intensive Care Medicine (if the link is paywalled, try this one)
Cohort Study | Association of obesity with disease outcome in multiple sclerosis.
8 Nov, 2022 | 12:07h | UTCNews Release: Obesity at MS diagnosis linked to higher current and subsequent levels of disability – BMJ
Commentary: Obesity Linked to Greater Disability, Poorer Outcomes in MS – HealthDay
RCT | Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen.
8 Nov, 2022 | 12:06h | UTCEffects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial – Journal of Allergy and Clinical Immunology (link to abstract – $ for full-text)
News Release: Monoclonal antibody improves cat allergen immunotherapy – National Institutes of Health
RCT | Efficacy of an eye-tracking-based dichoptic home treatment for amblyopia.
8 Nov, 2022 | 12:04h | UTC
Review | Oral anticoagulant use in patients with atrial fibrillation and chronic kidney disease.
8 Nov, 2022 | 12:02h | UTC
SR | Efficacy and safety of stereotactic body radiotherapy for painful bone metastases.
8 Nov, 2022 | 12:00h | UTC
M-A | Efficacy and safety of pharmacological interventions for pruritus in primary biliary cholangitis.
8 Nov, 2022 | 11:58h | UTC
SR | Pregnancy after living kidney donation.
8 Nov, 2022 | 11:56h | UTCVideo: Pregnancy after living kidney donation, a review of the available evidence and current guidance
Cohort Study | Menstrual cycle regularity and length across the reproductive lifespan and risk of cardiovascular disease.
8 Nov, 2022 | 11:54h | UTCCommentary: Irregular, Long Menstrual Cycles Up Risk for Cardiovascular Disease – HealthDay
Commentary on Twitter
Irregular and long menstrual cycles across a woman’s reproductive lifespan may identify women with a higher risk of cardiovascular disease, even after accounting for established CVD risk factors. #OAResearch #OAWeek https://t.co/BxNveNAqg5
— JAMA Network Open (@JAMANetworkOpen) October 29, 2022
M-A | Outcomes of dexmedetomidine vs. propofol sedation in critically ill adults requiring mechanical ventilation.
8 Nov, 2022 | 11:52h | UTC
Review | Continuous kidney replacement therapy.
8 Nov, 2022 | 11:51h | UTCContinuous KRT: A Contemporary Review – Clinical Journal of the American Society of Nephrology
Review | Radiographic contrast media and the kidney.
8 Nov, 2022 | 11:49h | UTCRadiographic Contrast Media and the Kidney – Clinical Journal of the American Society of Nephrology
CDC Clinical Practice Guideline for prescribing opioids for pain.
7 Nov, 2022 | 13:00h | UTCCommentaries:
CDC issues new opioid prescribing guidance, giving doctors more leeway to treat pain – NPR
SR | Efficacy and safety of IL-6 inhibition with biological DMARDs in immune-mediated inflammatory diseases.
8 Nov, 2022 | 11:47h | UTC
Commentary on Twitter
Check out our latest systematic literature review on IL-6 inhibition in immune-mediated inflammatory diseases:
▶️ positive clinical in a group of diseases
▶️ benefits in #COVID-19
▶️ similar safety outcomes vs other bDMARDs🔗 https://t.co/N1S9H2NrLQ pic.twitter.com/IAFGoEgkrY
— Annals of the Rheumatic Diseases (@eular_ARD) September 29, 2022
NICE Guideline | Self-harm: assessment, management and preventing recurrence.
7 Nov, 2022 | 12:58h | UTC
RCT | In patients with CKD (eGFR 20-45 mL/min per 1.73 m2), Empagliflozin reduced the risk of progression of kidney disease.
7 Nov, 2022 | 12:56h | UTCEmpagliflozin in Patients with Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease – medwire News
Video Summary: EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths
Commentary on Twitter
In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes than placebo. #KidneyWk https://t.co/HFgzPgrRFx pic.twitter.com/EPU6Rl14F1
— NEJM (@NEJM) November 4, 2022
RCT | Triglyceride lowering with Pemafibrate fails to reduce CVD risk in patients with Type 2 DM and hypertriglyceridemia.
7 Nov, 2022 | 12:54h | UTCTriglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk – New England Journal of Medicine (link to abstract – $ for full-text)
News Releases:
Commentaries:
Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT – TCTMD
Commentary on Twitter
In a randomized trial, the incidence of cardiovascular events was not lower in patients with diabetes, HTG, and low HDL cholesterol levels who received pemafibrate, although TG, VLDL cholesterol, remnant cholesterol, and Apo C-III levels decreased. #AHA22 https://t.co/bNtIAwWTX0 pic.twitter.com/yWaTWarlsv
— NEJM (@NEJM) November 5, 2022
RCT | Early amino acids in extremely preterm infants did improve neurodisability at 2 Years.
7 Nov, 2022 | 12:52h | UTCEarly Amino Acids in Extremely Preterm Infants and Neurodisability at 2 Years – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Extra Parenteral Amino Acids No Benefit for Extremely Preterm Infants – HealthDay
Commentary on Twitter
ProVIDE trial @NEJM: In ELBW infants, extra parenteral amino acids at a dose of 1 g/day for 5 days after birth did not improve survival free from neurodisability at 2 yrs.
Higher rates of mod-sev disability noted in intervention group.https://t.co/8hT3Ol3qOi#EBNEOalerts #neoEBM pic.twitter.com/2Z9qgkQF54— Evidence-Based Neo (@EBNEO) November 5, 2022
RCT | Chlortalidone and Hydrochlorothiazide resulted in similar reductions of CVD in older patients with hypertension.
7 Nov, 2022 | 12:50h | UTCNews Release (not published yet): No difference in heart outcomes found in use of two diuretics to treat blood pressure – American Heart Association
Commentaries:
In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE – TCTMD
Diuretic Comparison Project – DCP – American College of Cardiology